Articles of Association for Genmab A/S
August 18, 2016 14:03 ET
|
Genmab A/S
Genmab A/S has published its Articles of Association dated August 17, 2016. The Articles of Association can be found on Genmab’s website: http://ir.genmab.com/releases.cfm
Contact:
Rachel Curtis...
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
August 18, 2016 12:26 ET
|
Genmab A/S
Company Announcement
Copenhagen, Denmark; August 18, 2016 – In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, the persons below have...
Ledende medarbejderes og deres nærtståendes transaktioner med aktier og tilknyttede værdipapirer i Genmab A/S
August 18, 2016 12:26 ET
|
Genmab A/S
Selskabsmeddelelse
København, Danmark, 18. august 2016 – I henhold til artikel 19 i forordning nr. 596/2014 om markedsmisbrug og gennemførelsesforordning 2016/523 har nedenstående personer givet...
Genmab Announces Submission of Supplemental Biologics License Application to FDA for Daratumumab in Relapsed Multiple Myeloma
August 17, 2016 15:21 ET
|
Genmab A/S
Company Announcement
sBLA submitted to U.S. FDA for daratumumab for treatment of patients with relapsed multiple myeloma
Submission based on data from two Phase III studies, CASTOR and...
Genmab meddeler, at der er indsendt en supplerende registreringsansøgning til FDA for daratumumab til behandling af recidiverende myelomatose
August 17, 2016 15:21 ET
|
Genmab A/S
Selskabsmeddelelse
Supplerende registreringsansøgning (sBLA) indsendt til de amerikanske sundhedsmyndigheder (FDA) vedrørende anvendelse af daratumumab i patienter med recidiverende...
Ledende medarbejderes og deres nærtståendes transaktioner med aktier og tilknyttede værdipapirer i Genmab A/S
August 17, 2016 12:24 ET
|
Genmab A/S
Selskabsmeddelelse
København, Danmark, 17. august 2016 – I henhold til artikel 19 i forordning nr. 596/2014 om markedsmisbrug og gennemførelsesforordning 2016/523 har nedenstående...
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
August 17, 2016 12:24 ET
|
Genmab A/S
Company Announcement
Copenhagen, Denmark; August 17, 2016 – In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, the persons below have...
Kapitalforhøjelse i Genmab som følge af udnyttelse af medarbejderwarrants
August 17, 2016 12:01 ET
|
Genmab A/S
Selskabsmeddelelse
København, Danmark, 17. august 2016 – Genmab A/S (Nasdaq Copenhagen: GEN) forhøjer selskabets aktiekapital med 347.825 aktier som følge af udnyttelse af...
Capital Increase in Genmab as a Result of Employee Warrant Exercise
August 17, 2016 12:01 ET
|
Genmab A/S
Company Announcement
Copenhagen, Denmark; August 17, 2016 – Genmab A/S (Nasdaq Copenhagen: GEN) will increase its share capital by 347,825 shares as a consequence of the exercise of employee...
Genmab Enters Commercial License Agreement with Gilead for DuoBody® Technology
August 10, 2016 12:31 ET
|
Genmab A/S
Company Announcement
New commercial DuoBody technology platform collaboration with Gilead
Genmab granted Gilead an exclusive license to create a bispecific antibody with the DuoBody...